Study #2024-0475
GOG-3097 a phase 3, randomized, open-label study of combination therapy with Avutometinib plus Defactinib versus investigator's choice of treatment in patients with recurrent low-grade serous ovarian cancer (LGSOC).
MD Anderson Study Status
Enrolling
Treatment Agent
avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
Description
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Low Grade Serous Ovarian Cancer
Study phase:
Phase III
Physician name:
Lauren Cobb
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.